Point-of-Care Rapid RNA test for Zika CrossLife Technologies Inc. Project Summary/Abstract We aim to develop a rapid point-of-test that detects ZIKV at the point-of-need in < 30 minutes and is appropriate for non-laboratory settings and non-technical personnel. Our proprietary test exploits a novel probe reaction chemistry that allows multiplexed detection of DNA or RNA without sample purification, making it operable as a simple, hand-held test. Patient samples to be input directly into the device without pre- processing and a disposable cartridge carry out amplification of all targets and reports visible results that can be read by eye. We have demonstrated the feasibility of a novel and simple detection of ZIKV using TARA (Templated Assisted Rapid Assay). The key goals of the Phase 2 project are to 1) develop and evaluate automated paper strip device and to 2) validate it using clinical samples. We will evaluate the automated paper strip device using 200 samples from a Navy-IRB approved protocol through our CRADA collaboration with U.S. Naval Medical Research Center and the U.S. Naval Medical Research Unit SIX. We expect a sensitivity (>90%) and specificity (>90%) to the qRT-PCR data on the same samples. The successful achievement of 1) time to result < 30 min, 2) sensitivity > 90%, specificity > 90% and LOD < 500 copies/test, 3) > 90% user feedback on ease of use need for CLIA waiver, 4) requires no instrumentation, power source, or refrigeration of reagents, and 5) quantitative criteria for measuring the outcome of each task are exceeds or equivalent to the RT-PCR molecular test.

Public Health Relevance

Point-of-Care Rapid RNA test for Zika CrossLife Technologies, Inc. RESEARCH & RELATED Other Project Information Narrative The rapid spread of Zika virus through the Americas, together with the connection of infection with microcephaly and Guillain-Barr syndrome, have driven this previously overlooked virus into the spotlight. The World Health Organization (WHO) predicts almost four million people could be infected with Zika virus in the Americas in the year 2016.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
1R44TR003549-01
Application #
10138148
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Croucher, Leah Tolosa
Project Start
2021-01-15
Project End
2022-12-31
Budget Start
2021-01-15
Budget End
2021-12-31
Support Year
1
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Crosslife Technologies, Inc.
Department
Type
DUNS #
041375710
City
Carlsbad
State
CA
Country
United States
Zip Code
92008